Clinical Trial Results:
A phase II, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HP184 at 100, 200 and 400 mg doses administered orally once daily for twenty-four weeks in adult subjects with chronic spinal cord injury (CSCI)
Summary
|
|
EudraCT number |
2004-000763-98 |
Trial protocol |
GB DE |
Global completion date |
31 Dec 2004
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
04 Jun 2016
|
First version publication date |
04 Jun 2016
|
Other versions |
|
Summary report(s) |
DRI6213 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.